bms-986249,ipilimumab,nivolumab
bms,cytomx therapeutics
['bms-986249', 'bristol', 'bms']
cytomx therapeutics announces phase 1 data update for anti-ctla-4 probody therapeutic bms-986249 - presentation at esmo 2022 by collaborator, bristol myers squibb -- bms-986249 phase 2 study ongoing - south san francisco, calif., sept. 12, 2022 ... 
CEO Of Digital Media Online